Fast Five Quiz: Management of Advanced or Metastatic Triple-Negative Breast Cancer

Tanya Gupta, MD


July 27, 2023

Triple-negative breast cancer is a subtype that is defined by its lack of hormone receptors (ie, estrogen/progesterone), as well as a lack of overexpression/amplification of human epidermal growth factor receptor-2 (HER2). These breast tumors tend to be more aggressive, developing more often in patients who are premenopausal, and recurring earlier after diagnosis and treatment than other subtypes. Triple-negative breast cancer represents roughly 15%-20% of all breast tumors and carries the worst prognosis when it becomes metastatic, compared with other subtypes. Until very recently, single-agent chemotherapy or combinations of cytotoxic agents were the only therapies available to treat advanced or metastatic triple-negative breast cancer. A few new classes of therapeutic agents and approaches have been approved in the past 5 years; however, more effective, less toxic options are urgently needed.

What do you know about the management of advanced or metastatic triple-negative breast cancer? Test yourself with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.